ADVANCING BREAKTHROUGH THERAPEUTICS FOR CNS DISORDERS

Dr. Robert Discordia, Co-Founder, President & CEO of Equulus Therapeutics, brings 30+ years of leadership across the pharmaceutical and biotech industries. An expert in end-to-end drug development and CMC, he has advanced programs from preclinical through clinical development and commercialization across multiple modalities and therapeutic areas. He is recognized for building high-performing teams, optimizing global development and supply networks, and translating innovation into safe, effective medicines.

Dr. Peter Hendricks, Co-Founder, Director, and Chief Advisor on Clinical Psychology at Equulus Therapeutics, is the Heersink Endowed Professor in the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham. A clinical psychologist with deep expertise in CNS disorders and patient-centered outcomes, he has designed and led numerous clinical trials of psychedelic-assisted therapies. Bridging academic rigor with industry execution, he guides Equulus’ clinical psychology strategy to translate evidence into scalable, clinically meaningful therapeutics.

Dr. Bruce Blough, Co-Founder, Director on the Board of Directors, and Chief Advisor on Medicinal Chemistry at Equulus, is a veteran medicinal chemist focused on CNS therapeutics and translational drug design. Creator of Equulus’ Serotonin Releaser Technology—developed at Research Triangle Institute (RTI)—he advances novel, neurotherapeutics from hit discovery through lead optimization and IND-enabling studies. He brings decades of experience in SAR, scaffold engineering, and IP strategy, guiding portfolio chemistry, external collaborations, and CMC interfaces to deliver clinically viable candidates.

Co-Founder and Director on the Board of Equulus, Dr. Murnane is Associate Professor of Pharmacology, Toxicology & Neuroscience and of Psychiatry at LSU Health Shreveport  and serves as Director of Basic Science Research for the Louisiana Addiction Research Center. A specialist in neuropharmacology and neurotoxicology, his lab investigates addiction and stimulant-induced brain injury using behavioral pharmacology, receptor systems, neurochemistry, and neuroimaging. At Equulus, he guides preclinical model strategy, safety assessment, and mechanism-based decision thresholds that de-risk assets and accelerate IND-enabling progress.

Drew Mouton, Co-Founder, Director on the Board of Directors, and Chief Business Officer (CBO) of Equulus Therapeutics, advises on corporate strategy, business development, and capital formation.
A seasoned operator, he has driven partnering, licensing, and alliance management; built portfolio and go-to-market strategies; and structured both dilutive and non-dilutive financings to advance clinical programs. At Equulus, he advises on investor relations and strategic collaborations that accelerate our CNS pipeline and build durable enterprise value.